Objectives: We investigated the association between persistent low-level viraemia, measured as viraemia copy-years (VCY), and all-cause mortality. Methods: We included 3271 HIV-infected patients who initiated their first combined ART (cART) during 1998- 2012 enrolled in the multicentre Italian MASTER cohort. VCY was defined as the area under the curve of plasma viral load (pVL) and expressed in log10 copies.years/mL. VCY was evaluated from cART initiation until the end of follow-up [VCY-overall (VCY-o)], and stratified into before [VCY-early (VCY-e)] and after [VCY-late (VCY-l)] the eighth month from starting cART, and as the ratio of VCY-l to follow-up duration (VCY-l/FUD). Results: The risk of death increased of about 40% for higher than the median levels of VCY-o and VCY-e. Compared with subjects with permanently suppressed pVL after the eighth month from starting cART, mortality increased by 70% for those with VCY-l =≥3 log10 copies.years/mL, and by about 20-fold for those with VCY-l/FUD =≥2.3 log10 copies/mL. Patients who maintained low levels of VCY-l (<,3 log10 copies.years/mL) or VCY-l/FUD (<,2.3 log10 copies/mL) had a risk of death similar to patients with permanently suppressed pVL. CD4 cell count at baseline was predictive of high risk of death only in subjects with VCY-l =≥3 log10 copies.years/mL. Conclusions: The risk of death did not increase in HIV-infected patients with low levels of VCY-l compared with patients with permanent virological suppression.
Quiros-Roldan, E., Raffetti, E., Castelli, F., Focà, E., Castelnuovo, F., Di Pietro, M., et al. (2016). Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(12) [10.1093/jac/dkw307].
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study
Gori, A;
2016
Abstract
Objectives: We investigated the association between persistent low-level viraemia, measured as viraemia copy-years (VCY), and all-cause mortality. Methods: We included 3271 HIV-infected patients who initiated their first combined ART (cART) during 1998- 2012 enrolled in the multicentre Italian MASTER cohort. VCY was defined as the area under the curve of plasma viral load (pVL) and expressed in log10 copies.years/mL. VCY was evaluated from cART initiation until the end of follow-up [VCY-overall (VCY-o)], and stratified into before [VCY-early (VCY-e)] and after [VCY-late (VCY-l)] the eighth month from starting cART, and as the ratio of VCY-l to follow-up duration (VCY-l/FUD). Results: The risk of death increased of about 40% for higher than the median levels of VCY-o and VCY-e. Compared with subjects with permanently suppressed pVL after the eighth month from starting cART, mortality increased by 70% for those with VCY-l =≥3 log10 copies.years/mL, and by about 20-fold for those with VCY-l/FUD =≥2.3 log10 copies/mL. Patients who maintained low levels of VCY-l (<,3 log10 copies.years/mL) or VCY-l/FUD (<,2.3 log10 copies/mL) had a risk of death similar to patients with permanently suppressed pVL. CD4 cell count at baseline was predictive of high risk of death only in subjects with VCY-l =≥3 log10 copies.years/mL. Conclusions: The risk of death did not increase in HIV-infected patients with low levels of VCY-l compared with patients with permanent virological suppression.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.